Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis finally struck a deal to acquire Genzyme for $20.1 billion plus potential future payments, but successfully integrating the company remains the challenge.

You may also be interested in...



BioMarin Negotiates For Aldurazyme With Sanofi-Aventis

The mash-up between Sanofi and Genzyme will have a large effect on one of the biotech's other partners.

BioMarin Negotiates For Aldurazyme With Sanofi-Aventis

The mash-up between Sanofi and Genzyme will have a large effect on one of the biotech's other partners.

In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal

MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel